Application of fructus amomi volatile oil and / or bornyl acetate in preparation of medicine for preventing and / or treating preeclampsia

By using Amomum volatile oil and/or longanine acetate, the adverse reactions and complex administration of existing preeclampsia treatment drugs have been solved, which significantly alleviates hypertension, proteinuria and placental dysfunction, promotes fetal growth, and repairs blood vessels. and intestinal barriers provide a simple, safe and effective treatment plan.

CN118924856APending Publication Date: 2024-11-12SOUTHERN MEDICAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411007039.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-25
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

There are many adverse reactions to existing preeclampsia treatment drugs, and the treatment methods in low- and middle-income countries are complex, making it difficult to be simple, safe and effective.

Method used

Amomum volatile oil and/or its main ingredient longa acetate are used to obtain Amomum volatile oil by grinding, soaking and distillation, and the pathological status of preeclampsia is simulated by subcutaneous injection of nitrosolevarginine methyl ester, and oral Amomum volatile oil is taken. or longanolacetate acetate to prevent and treat preeclampsia.

Benefits of technology

Significantly alleviate hypertension and proteinuria caused by preeclampsia, repair the structure and function of the placenta, promote intrauterine growth and development of the fetus, correct the imbalance between angiogenesis and anti-angiogenic factors, reduce placental inflammation, reduce intestinal permeability, and reduce pregnancy Maternal colonic injury provides comprehensive therapeutic effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924856A_ABST
    Figure CN118924856A_ABST
Patent Text Reader

Abstract

The invention discloses application of fructus amomi volatile oil and / or bornyl acetate in preparation of a medicine for preventing and / or treating preeclampsia. The invention also discloses application of fructus amomi volatile oil and / or bornyl acetate in preparation of a medicine for preventing and / or treating hypertension caused by preeclampsia, or a medicine for preventing and / or treating proteinuria caused by preeclampsia, or a medicine for reversing placenta weight reduction caused by preeclampsia. The invention relates to a medicine for recovering fetal intrauterine growth limitation caused by preeclampsia, a medicine for recovering placenta tissue pathological damage or placenta dysfunction caused by preeclampsia, a medicine for recovering angiogenesis and anti-angiogenesis factor imbalance caused by preeclampsia, or a medicine for relieving colitis caused by preeclampsia, or a medicine for recovering fetal intrauterine growth limitation caused by preeclampsia, or a medicine for recovering placenta tissue pathological damage or placenta dysfunction caused by preeclampsia. The invention also relates to application of the traditional Chinese medicine composition in medicines for repairing colon barrier injury or intestinal permeability increase caused by preeclampsia. The traditional Chinese medicine composition overcomes the limitations of single effect and adverse reaction of gastrointestinal tracts in the current preeclampsia treatment medicine.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine, and particularly relates to application of Amomum villosum volatile oil and / or bornyl acetate in preparing medicines for preventing and / or treating preeclampsia. Background Art

[0002] Pre-eclampsia (PE) is a complex pregnancy-specific disease with hypertension (systolic blood pressure ≥140 mmHg and / or diastolic blood pressure ≥90 mmHg) and proteinuria as the main clinical features, often accompanied by neurological symptoms such as headache, convulsions, and visual impairment. In severe cases, PE can cause damage to important organs such as the liver and kidneys, leading to systemic multi-organ failure and even maternal and infant death. Compared with normal pregnant women, patients with preeclampsia have a shortened life expectancy, a significantly increased risk of stroke, cardiovascular disease, and diabetes, and infants with preeclampsia also have a significantly increased risk of premature birth, neurodevelopmental disorders, and cardiovascular and metabolic diseases. Therefore, the prevention and treatment of preeclampsia is of great significance to promoting reproductive health.

[0003] The pathogenesis of PE is complex and involves a variety of pathological factors, including abnormal uterine-placental vascular structure, endothelial dysfunction, inflammatory immune overactivation, and genetic factors. At present, the "two-stage model" theory is clinically recognized as the main pathogenesis of PE. Under normal pregnancy conditions, the uterine spiral arteries of pregnant women will expand to 5-10 times the normal size, developing into wider, broader, and higher-flow arteries, which deliver a large amount of blood, oxygen, and nutrients to the fetus to ensure the normal development of the fetus in the uterus. When preeclampsia occurs, the mother's uterine spiral arteries are narrowed due to abnormal remodeling, which can lead to insufficient blood and oxygen supply to the placenta, and then cause placental dysfunction, which is not conducive to the delivery of blood oxygen and nutrients, resulting in restricted fetal growth and development. In order to compensate for the insufficient blood oxygen supply to the placenta, the mother increases blood pressure by constricting blood vessels, driving more blood to the placenta, leading to the occurrence of hypertension, which is one of the main clinical symptoms of PE. In addition, due to maternal placental dysfunction, a large number of placental-derived bioactive substances are released into the maternal blood circulation, including anti-angiogenic factors, inflammatory cytokines, etc., which can induce endothelial dysfunction and inflammatory response, further damage the normal contraction and relaxation function of blood vessels, reduce blood flow to various organs, and lead to multiple organ dysfunction such as liver, kidney, and lung, especially involving renal tissue, damaging glomerular filtration function, thereby causing the production of urinary protein, which is also one of the main clinical symptoms of PE.

[0004] At present, the treatment strategies for preeclampsia mainly include preventive treatment and symptomatic treatment. According to the "Recommendations for Clinical Trials on Screening and Prevention of Preeclampsia in Single Pregnancy" issued by the International Federation of Gynecology and Obstetrics (FIGO), pregnant women with high risk of preeclampsia can take low-dose (<300 mg / day) aspirin orally every day from 12-16 weeks of pregnancy to reduce the occurrence of preeclampsia. In addition, the "Guidelines for the Diagnosis and Treatment of Hypertensive Disorders Complicating Pregnancy (2020)" recommends taking oral labetalol, nifedipine and other drugs to control high blood pressure, and intravenous magnesium sulfate to reduce the occurrence of convulsions and spasms. However, there are still many adverse reactions to existing treatments. Preventive drug aspirin can cause gastrointestinal symptoms such as nausea, vomiting, and upper abdominal pain. The antihypertensive drug labetalol, as a negative cardiac inotropic drug, can promote pulmonary edema and heart failure and may cause bronchospasm. In addition, symptoms of headache and nausea may occur within 24 hours after taking the drug. As a calcium channel antagonist, nifedipine can rapidly dilate blood vessels and thus lower blood pressure, but it is accompanied by adverse reactions such as severe headache (especially within 24 hours of taking the medicine), dizziness, flushing, palpitations, and ankle swelling. Sublingual administration of nifedipine is supported for the rapid correction of severe hypertension in pregnant women, but it may lead to reduced placental perfusion, causing acute fetal distress. In addition, the use of magnesium sulfate in patients with preeclampsia can reduce the risk of eclamptic attacks by 58%. Because intramuscular injection can cause bruising or abscesses, the best way to administer magnesium sulfate is intravenous administration. However, because intravenous administration is difficult to operate and requires professional medical skills, and eclampsia is more common in low- and middle-income countries than in high-income countries, it is very important to find a safe and effective drug for the treatment of preeclampsia that is easy to administer. Summary of the invention

[0005] In order to solve the deficiencies in the prior art, the present invention aims to provide the use of Amomum villosum volatile oil and / or bornyl acetate in the preparation of a drug for preventing and / or treating preeclampsia.

[0006] Amomum villosum Lour. is the dried mature fruit of the herbaceous plant of the ginger family. It is one of the four major southern medicines in my country and has the effects of removing dampness and stimulating appetite, warming the spleen and stopping diarrhea, regulating qi and calming the fetus. Amomum villosum is composed of a variety of chemical substances, including volatile components (borneol acetate, borneol, etc.) and non-volatile components (polysaccharides, flavonoids, etc.). The present invention finds that Amomum villosum volatile oil and its main component, bornyl acetate, play an important role in preventing and treating preeclampsia.

[0007] The specific technical solutions of the present invention are as follows:

[0008] The present invention provides application of Amomum villosum volatile oil and / or bornyl acetate in preparing medicine for preventing and / or treating preeclampsia.

[0009] The present invention also provides the use of Amomum villosum volatile oil and / or bornyl acetate in the preparation of a medicine for preventing and / or treating hypertension caused by preeclampsia.

[0010] The present invention also provides the use of Amomum villosum volatile oil and / or bornyl acetate in the preparation of a medicine for preventing and / or treating proteinuria caused by preeclampsia.

[0011] The present invention also provides the use of Amomum villosum volatile oil and / or bornyl acetate in preparing a medicine for reversing the reduction of placental weight caused by preeclampsia.

[0012] The present invention also provides the use of Amomum villosum volatile oil and / or bornyl acetate in the preparation of a medicine for recovering fetal intrauterine growth restriction caused by preeclampsia.

[0013] The present invention also provides the use of Amomum villosum volatile oil and / or bornyl acetate in the preparation of a medicine for restoring pathological damage of placental tissue or abnormal placental function caused by preeclampsia.

[0014] The present invention also provides the use of Amomum villosum volatile oil and / or bornyl acetate in preparing a drug for restoring the imbalance of angiogenesis and anti-angiogenesis factors caused by preeclampsia or a drug for alleviating colon inflammation caused by preeclampsia.

[0015] The present invention also provides the use of Amomum villosum volatile oil and / or bornyl acetate in the preparation of a medicine for repairing colon barrier damage or increased intestinal permeability caused by preeclampsia.

[0016] Furthermore, the Amomum villosum volatile oil is prepared by the following method:

[0017] 1) grinding and crushing the Amomum villosum, discarding the shell of the Amomum villosum, and obtaining crushed Amomum villosum;

[0018] 2) adding deionized water to the crushed Amomum villosum, soaking the Amomum villosum, and obtaining the Amomum villosum and its soaking liquid;

[0019] 3) Heat the Amomum villosum and its soaking liquid to a slightly boiling state, and collect the distillate, which is the Amomum villosum volatile oil.

[0020] Furthermore, in step 2), the weight ratio of deionized water to Amomum villosum is 10:1-50:1;

[0021] And / or, the soaking time in step 2) is 30-120 min;

[0022] And / or, the heating temperature in step 3) is 80-95° C. and the heating time is 5-8 h.

[0023] The beneficial effects of the present invention are:

[0024] The present invention simulates the pathological state of preeclampsia by subcutaneous injection of nitroso-L-arginine methyl ester solution (125 mg / kg), and intragastrically administers Amomum villosum volatile oil (18 mg / kg) or borneol acetate (8.7 mg / kg) once a day from the 9th day of pregnancy until the end of pregnancy. It is found that oral administration of Amomum villosum volatile oil and its main component borneol acetate has a good therapeutic effect on preeclampsia.

[0025] Compared with drugs with single therapeutic effects such as the antihypertensive drug labetalol and the antispasmodic drug magnesium sulfate, oral administration of Amomum villosum volatile oil or its main ingredient borneol acetate can significantly relieve hypertension and proteinuria caused by preeclampsia, repair placental structure and function, promote fetal intrauterine growth and development, correct the imbalance of angiogenic and anti-angiogenic factors, and reduce placental inflammation.

[0026] Compared with preventive drugs such as aspirin and antihypertensive drug labetalol that have gastrointestinal adverse reactions, oral administration of Amomum villosum volatile oil can significantly reduce the expression of colon inflammatory factors, increase the content of tight junction proteins, thereby repairing the intestinal barrier, reducing the increased intestinal permeability caused by PE, and alleviating PE-induced maternal colon damage, showing a more comprehensive therapeutic effect and providing a new therapeutic drug for the prevention or treatment of preeclampsia. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 Comparison of blood pressure of mice in each group in Example 1 (n=6). Wherein, a represents the comparison of systolic blood pressure between PE group and NP group on the corresponding day; b represents the comparison of systolic blood pressure between PE group and VOA group on the corresponding day; c represents the comparison of systolic blood pressure between PE group and BA group on the corresponding day.

[0028] Figure 2 Comparison of urine protein content in each group of mice in Example 2 (n=6).

[0029] Figure 3 Comparison of placenta weights of mice in each group in Example 3 (n=6).

[0030] Figure 4 This is a comparison of the placental partitions of mice in each group in Example 4 (n=6). The scale bar in the figure is 1000 μm.

[0031] Figure 5 Comparison of fetal weights of mice in each group in Example 5 (n=6).

[0032] Figure 6 This is a comparison of the levels of angiogenic and anti-angiogenic factors in the serum and placenta of each group of mice in Example 6 (n=6).

[0033] Figure 7Comparison of the relative mRNA expression levels of inflammatory factors and tight junction proteins in the colon of each group of mice in Example 7 (n=6).

[0034] Figure 8 These are representative images and quantitative images of immunohistochemical staining of tight junction proteins in the colon of each group of mice in Example 7 (n=6).

[0035] Fig. 9 Comparison of endotoxin content in the serum of each group of mice in Example 8 (n=6). DETAILED DESCRIPTION

[0036] In order to understand the present invention more clearly, the present invention is further described with reference to the following examples and accompanying drawings. The examples are only used for explanation and are not intended to limit the present invention in any way. In the examples, each raw material reagent is commercially available, and the experimental methods without specifying specific conditions are conventional methods and conventional conditions well known in the art, or according to the conditions recommended by the instrument manufacturer.

[0037] 1. Drug ingredients

[0038] (1) Volatile oil of Aomomum villosum Lour. (VOA) in the embodiment of the present invention is prepared by the following preparation method:

[0039] 1) Weigh 30 g of Amomum villosum, grind and crush it, and discard the shell of Amomum villosum;

[0040] 2) Take 10 times the weight of Amomum villosum in deionized water (300 mL), pour the crushed Amomum villosum into the water and soak for 30 minutes;

[0041] 3) heating the Amomum villosum and its soaking liquid to a slightly boiling state (85° C. in this embodiment) for 5 hours and collecting the Amomum villosum volatile oil;

[0042] 4) The volume of the extracted Amomum villosum volatile oil was read after standing in the extractor for 1 hour;

[0043] 5) Store the Amomum villosum volatile oil at 4°C away from light.

[0044] (2) Bornyl acetate (BA), chemical formula: C 12 H 20 O2, with a molecular weight of 196.29, is the component with the highest content in the volatile oil of Amomum villosum.

[0045] 2. Experimental Animals

[0046] Male and female C57BL / 6 mice (8–10 weeks, weighing 18–20 g) were purchased from SPF (Beijing, China) Biotechnology Co., Ltd. (Beijing, China). Mice were housed under standard light and dark cycles (12 h:12 h) with free access to food and water. After one week of acclimation, healthy male mice were mated with female mice at a ratio of 1:2 overnight. Female mice with sperm plugs were considered pregnant, and this day was defined as gestational day (GD0). All animal studies were performed in accordance with the protocols and guidelines approved by the Animal Ethics Committee of the Laboratory Animal Center of Southern Medical University.

[0047] 3. Experimental reagents

[0048]

[0049] 4. Drug preparation

[0050] 1) N-nitro-L-arginine methyl ester (L-NAME) solution: Weigh 125 mg of L-NAME powder and dilute to 10 mL with normal saline.

[0051] 2) Amomum villosum volatile oil solution: measure 9 μL of Amomum villosum volatile oil, dilute to 5 mL with normal saline, mix thoroughly, and use immediately after preparation.

[0052] 3) Bornyl acetate solution: Measure 4.35 μL of bornyl acetate, dilute to 5 mL with normal saline, mix thoroughly, and use immediately after preparation.

[0053] 5. Establishment and evaluation of preeclampsia model

[0054] 1) Establishment of preeclampsia model

[0055] Starting from GD9, pregnant mice were subcutaneously injected with 125 mg / kg of nitroso-L-arginine methyl ester (L-NAME) solution every day for 9 days.

[0056] 2) Evaluation of preeclampsia model

[0057] Blood pressure: The model was successfully established when the systolic blood pressure of the mice in the model group was >110 mmHg.

[0058] Proteinuria: The model was successfully established when the urine protein content of mice in the model group was significantly higher than 15.0 mg / dL.

[0059] 6. Real-time fluorescence quantitative PCR

[0060] 1) RNA reverse transcription reaction

[0061] According to the method described in the reverse transcription kit, prepare a 20 μL total reaction system. Add the RNA required for the sample and 4 μL of HiScript IIQ RT SuperMix for qPCR reagent to a 200 μL PCR tube, and add ddH2O to 20 μL. Place the PCR tube in a PCR amplification instrument and perform the following operating conditions: 50°C, 15 min; 85°C, 5 s; 4°C, ∞. After the reaction is completed, centrifuge, mark the time, and store the obtained cDNA at -80°C for later use.

[0062] 2) Real-time quantitative PCR (RT-qPCR)

[0063] All reverse transcription products were subjected to real-time fluorescence quantitative PCR, and the reaction system is shown in Table 1. The primer sequences of related genes are shown in Table 2, and a two-step PCR amplification system was used, and the method settings are shown in Table 3.

[0064] Table 1 PCR reaction system

[0065]

[0066] Table 2 Primer sequences

[0067]

[0068] Table 3 RT-qPCR reaction procedure

[0069]

[0070] Data processing: Gapdh was used as the internal reference gene, and the relative expression level of the target gene was calculated by the 2-ΔΔCt method.

[0071] Example 1: Amomum villosum volatile oil and bornyl acetate can significantly restore hypertension caused by preeclampsia

[0072] Hypertension is the most critical clinical indicator of preeclampsia. This example investigates the effects of Amomum villosum volatile oil and bornyl acetate on the blood pressure of mice with preeclampsia. In this example, mice were randomly divided into 4 groups: a normal pregnancy group (NP, n = 6), a preeclampsia model group (PE, n = 6), an Amomum villosum volatile oil group (VOA, n = 6), and a bornyl acetate group (BA, n = 6). Mice in the VOA group and the BA group were gavaged with Amomum villosum volatile oil (18 mg / kg) and bornyl acetate (8.7 mg / kg) from the 9th day of pregnancy (GD 9), and mice in the normal pregnancy group and the preeclampsia model group were gavaged with an equal volume of 0.9% saline. Once a day for 9 days.

[0073] The blood pressure comparison results of each group of mice are as follows Figure 1The results showed that the blood pressure of mice in the preeclampsia model group was significantly higher than that in the normal pregnancy group, the Amomum villosum volatile oil group and the borneol acetate group after GD9, indicating that both VOA and BA can significantly reduce the blood pressure of mice in preeclampsia.

[0074] Example 2: Amomum villosum volatile oil and bornyl acetate can significantly restore proteinuria caused by preeclampsia

[0075] Proteinuria is one of the key clinical indicators of preeclampsia. In this example, subcutaneous injection of nitroso-L-arginine methyl ester (L-NAME) solution was used to simulate the disease state during the natural onset of preeclampsia, and the effects of Amomum villosum volatile oil and borneol acetate on urinary protein in mice with preeclampsia were investigated. In this example, mice were randomly divided into 4 groups: a normal pregnancy group (NP, n = 6), a preeclampsia model group (PE, n = 6), an Amomum villosum volatile oil group (VOA, n = 6), and a borneol acetate group (BA, n = 6). Mice in the VOA group and the BA group were gavaged with Amomum villosum volatile oil (18 mg / kg) and borneol acetate (8.7 mg / kg) from the 9th day of pregnancy (GD 9), and mice in the normal pregnancy group and the preeclampsia model group were gavaged with the same volume of 0.9% saline. Once a day for 9 days.

[0076] The comparison results of urine protein content of mice in each group are shown in Figure 2 The results showed that the urine protein content of preeclampsia model mice was significantly higher than that of the normal pregnancy group, and the urine protein level of model mice was significantly downregulated after intervention with Amomum villosum volatile oil or bornyl acetate, indicating that both VOA and BA can significantly reduce the proteinuria symptoms of preeclampsia model mice.

[0077] Example 3: Amomum villosum volatile oil and bornyl acetate can increase the placenta weight of preeclampsia mice

[0078] The placenta is rich in blood vessels and nutrients, which provide the necessary substances for fetal growth and development. This example investigates the effects of Amomum villosum volatile oil and bornyl acetate on the weight of the placenta in mice with preeclampsia. In this example, mice were randomly divided into 4 groups: a normal pregnancy group (NP, n = 6), a preeclampsia model group (PE, n = 6), an Amomum villosum volatile oil group (VOA, n = 6), and a bornyl acetate group (BA, n = 6). Mice in the VOA group and the BA group were gavaged with Amomum villosum volatile oil (18 mg / kg) and bornyl acetate (8.7 mg / kg) from the 9th day of pregnancy (GD 9), and mice in the normal pregnancy group and the preeclampsia model group were gavaged with the same volume of 0.9% saline. Once a day for 9 days.

[0079] The comparison results of placenta weight of each group of mice are as follows Figure 3The results showed that compared with the mice in the normal pregnancy group, the placental weight of the mice in the preeclampsia group was significantly reduced, while the intervention of Amomum villosum volatile oil or bornyl acetate significantly reversed the decrease in placental weight, indicating that the intervention of VOA and BA is beneficial to the growth and development of the placenta in preeclampsia.

[0080] Example 4: Amomum villosum volatile oil and bornyl acetate can restore placental dysfunction

[0081] The placenta is mainly divided into three parts: the decidual region, the connecting region and the labyrinth region. The placental labyrinth region is mainly involved in the synthesis of hormones and cytokines (such as angiogenic factors and anti-angiogenic factors), maintaining normal placental function and fetal growth. The placental connecting region is mainly responsible for the exchange of oxygen, nutrients and metabolic waste. This example investigates the effects of Amomum villosum volatile oil and borneol acetate on placental function in mice with preeclampsia. In this example, mice were randomly divided into 4 groups: a normal pregnancy group (NP, n = 6), a preeclampsia model group (PE, n = 6), an Amomum villosum volatile oil group (VOA, n = 6), and a borneol acetate group (BA, n = 6). Mice in the VOA group and the BA group were gavaged with Amomum villosum volatile oil (18 mg / kg) and borneol acetate (8.7 mg / kg) from the 9th day of pregnancy (GD 9), and mice in the normal pregnancy group and the preeclampsia model group were gavaged with the same volume of 0.9% saline. Once a day for 9 days.

[0082] HE staining results Figure 4 As shown in the figure. The ratio of the labyrinth area to the connection area of ​​the placenta of PE mice was significantly higher than that of NP mice, indicating that the placental structure of PE mice was pathologically damaged. This phenomenon was reversed after intervention with VOA or BA, indicating that VOA and BA can repair the pathological damage of the placental tissue of PE mice and restore the abnormal placental function.

[0083] Example 5: Amomum villosum volatile oil and bornyl acetate can restore intrauterine growth restriction in pregnant mice with preeclampsia

[0084] Fetal growth restriction is one of the main complications of preeclampsia. This example investigates the effects of Amomum villosum volatile oil and bornyl acetate on fetal growth in mice with preeclampsia. In this example, mice were randomly divided into 4 groups: a normal pregnancy group (NP, n = 6), a preeclampsia model group (PE, n = 6), an Amomum villosum volatile oil group (VOA, n = 6), and a bornyl acetate group (BA, n = 6). Mice in the VOA group and the BA group were gavaged with Amomum villosum volatile oil (18 mg / kg) and bornyl acetate (8.7 mg / kg) from the 9th day of pregnancy (GD 9), and mice in the normal pregnancy group and the preeclampsia model group were gavaged with an equal volume of 0.9% saline. Once a day for 9 days.

[0085] The comparison results of fetal weights of mice in each group are shown in Figure 5The results showed that compared with the mice in the normal pregnancy group, the fetal weight of the mice in the preeclampsia group was significantly reduced, while the intervention of VOA or BA could significantly reverse the decrease in fetal weight, indicating that VOA and BA can promote fetal growth and development in PE pregnant mice.

[0086] Example 6: Amomum villosum volatile oil and bornyl acetate can restore the imbalance of angiogenic and anti-angiogenic factors

[0087] In the development of preeclampsia, due to abnormal function of the vascular system, an imbalance of angiogenesis and anti-angiogenic factors is caused, which affects the remodeling of uterine spiral arteries. This example investigates the effects of Amomum villosum volatile oil and borneol acetate on angiogenesis and anti-angiogenic factors in preeclampsia. In this example, mice were randomly divided into 4 groups: a normal pregnancy group (NP, n = 6), a preeclampsia model group (PE, n = 6), an Amomum villosum volatile oil group (VOA, n = 6), and a borneol acetate group (BA, n = 6). Mice in the VOA group and the BA group were gavaged with Amomum villosum volatile oil (18 mg / kg) and borneol acetate (8.7 mg / kg) from the 9th day of pregnancy (GD 9), and mice in the normal pregnancy group and the preeclampsia model group were gavaged with the same volume of 0.9% saline. Once a day for 9 days.

[0088] The content of angiogenic and anti-angiogenic factors in serum was obtained by ELISA, and the content of angiogenic and anti-angiogenic factors in placenta was obtained by RT-qPCR. Figure 6 As shown in the data, compared with the model group, soluble fms-like tyrosine kinase-1 (sFlt-1, an anti-angiogenic factor) in the serum and placenta of PE pregnant mice was significantly decreased, angiogenic factor (VEGF) and placental growth factor (PIGF) were significantly increased after VOA or BA intervention, and the disease indicator sFlt-1 / PIGF of PE was significantly decreased, indicating that VOA and BA can restore the imbalance of angiogenic and anti-angiogenic factors.

[0089] Example 7: Amomum villosum volatile oil can repair colon barrier damage caused by preeclampsia

[0090] In recent years, the imbalance of intestinal microecology has been considered as one of the pathogenesis of PE. Due to the disorder of intestinal flora and damaged intestinal barrier, pathogenic bacteria are transferred from the intestine to the placenta through the blood circulation, resulting in abnormal immune response, thereby inducing PE. Among them, the aggravation of inflammatory response will further lead to the destruction of the tight junction structure of the intestine. This example investigates the effect of Amomum villosum volatile oil on colon barrier damage in preeclampsia. In this example, mice were randomly divided into 3 groups: normal pregnancy group (NP, n = 6), preeclampsia model group (PE, n = 6), Amomum villosum volatile oil group (VOA, n = 6), n = 6). Mice in the VOA group were gavaged with Amomum villosum volatile oil (18 mg / kg) from the 9th day of pregnancy (GD 9), and mice in the normal pregnancy group and preeclampsia model group were gavaged with the same volume of 0.9% saline. Once a day for 9 days.

[0091] The results are as follows Figure 7-8 As shown, compared with the model group, VOA intervention significantly reduced the expression of inflammatory factors (Il-6, Il-1β, Tnf-α) in the colon of preeclampsia mice, significantly increased the levels of tight junction proteins (ZO-1, Occludin and Claudin-1), and repaired PE-induced intestinal barrier damage.

[0092] Example 8: Amomum villosum volatile oil can repair increased intestinal permeability caused by preeclampsia

[0093] The intestine contains a large number of Gram-negative bacteria, and endotoxin (LPS) is a heat-resistant lipopolysaccharide molecule on the cell wall of Gram-negative pathogenic bacteria. When the intestinal barrier function is impaired, LPS will enter the blood and transfer to the surrounding tissues and organs, causing damage to the surrounding tissues and organs. This example investigates the effect of Amomum villosum volatile oil on intestinal permeability caused by preeclampsia. In this example, mice were randomly divided into 3 groups: normal pregnancy group (NP, n = 6), preeclampsia model group (PE, n = 6), Amomum villosum volatile oil group (VOA, n = 6), n = 6). Mice in the VOA group were gavaged with Amomum villosum volatile oil (18 mg / kg) from the 9th day of pregnancy (GD 9), and mice in the normal pregnancy group and preeclampsia model group were gavaged with the same volume of 0.9% saline. Once a day for 9 days.

[0094] The results are as follows Fig. 9 As shown in the figure, compared with the model group, the LPS in the serum of PE pregnant mice was significantly reduced after VOA intervention, indicating that VOA reduced the intestinal permeability of PE pregnant mice.

[0095] Obviously, the above embodiments are merely examples for the purpose of clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived therefrom are still within the scope of protection of the invention.

Claims

1. Use of Amomum villosum volatile oil and / or bornyl acetate in the preparation of a drug for preventing and / or treating preeclampsia.

2. Use of Amomum villosum volatile oil and / or bornyl acetate in the preparation of a drug for preventing and / or treating hypertension caused by preeclampsia.

3. Use of Amomum villosum volatile oil and / or bornyl acetate in the preparation of a drug for preventing and / or treating proteinuria caused by preeclampsia.

4. Use of Amomum villosum volatile oil and / or bornyl acetate in the preparation of a drug for reversing placental weight reduction caused by preeclampsia.

5. Use of Amomum villosum volatile oil and / or bornyl acetate in the preparation of a drug for restoring fetal intrauterine growth restriction caused by preeclampsia.

6. Use of Amomum villosum volatile oil and / or bornyl acetate in the preparation of a drug for restoring pathological damage to placental tissue or abnormal placental function caused by preeclampsia.

7. Use of Amomum villosum volatile oil and / or bornyl acetate in the preparation of a drug for restoring the imbalance between angiogenesis and anti-angiogenesis factors caused by preeclampsia or a drug for alleviating colon inflammation caused by preeclampsia.

8. Use of Amomum villosum volatile oil and / or bornyl acetate in the preparation of drugs for repairing colon barrier damage or increased intestinal permeability caused by preeclampsia.

9. The use according to any one of claims 1 to 8, It is characterized in that The Amomum villosum volatile oil is prepared by the following method: 1) grinding and crushing the Amomum villosum, discarding the shell of the Amomum villosum, and obtaining crushed Amomum villosum; 2) adding deionized water to the crushed Amomum villosum, soaking the Amomum villosum, and obtaining the Amomum villosum and its soaking liquid; 3) Heat the Amomum villosum and its soaking liquid to a slightly boiling state, and collect the distillate, which is the Amomum villosum volatile oil.

10. The use according to claim 9, It is characterized in that The weight ratio of deionized water to Amomum villosum in step 2) is 10:1-50:1; And / or, the soaking time in step 2) is 30-120 min; And / or, the heating temperature in step 3) is 80-95° C. and the heating time is 5-8 h.